SCHEMBL648371

SCHEMBL648371

COC(=O)c1ccccc1OS(C)(=O)=O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.69
SLC6A3 Q01959 3/20 0.56
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA5A P35218 1/20 0.53
CA9 Q16790 1/20 0.53
KMT2A Q03164 4/20 0.53
TSHR P16473 3/20 0.52
LMNA P02545 1/20 0.52
HSD17B10 Q99714 2/20 0.50
SLC6A4 P31645 2/20 0.50
ALDH1A1 P00352 1/20 0.50
CFTR P13569 1/20 0.50
HTT P42858 1/20 0.49
KDM4E B2RXH2 1/20 0.49
POLB P06746 1/20 0.49
ATM Q13315 1/20 0.49
MAPT P10636 3/20 0.48
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7113435 0.86 L3MBTL1 (0.65) L3MBTL1SLC6A3CA1CA2CA5A
SCHEMBL27480641 0.86 L3MBTL1 (0.69) L3MBTL1SLC6A3CA1CA2CA5A
SCHEMBL21034056 0.84 L3MBTL1 (0.67) L3MBTL1SLC6A3CA1CA2CA5A
SCHEMBL8606486 0.83 L3MBTL1 (0.65) L3MBTL1SLC6A3CA1CA2CA5A
SCHEMBL4731724 0.81 LMNA (0.51) L3MBTL1KMT2ATSHRLMNAHSD17B10
SCHEMBL2478066 0.81 KDM4E (0.56) L3MBTL1KMT2ATSHRLMNAHSD17B10
SCHEMBL3529817 0.81 L3MBTL1 (1.00) L3MBTL1SLC6A3CA1CA2CA5A
SCHEMBL1665977 0.81 MAPT (0.70) L3MBTL1SLC6A3CA1CA2CA5A
SCHEMBL14198530 0.81 MAPT (0.70) L3MBTL1SLC6A3KMT2ATSHRLMNA
SCHEMBL28495110 0.80 KDM4E (0.49) L3MBTL1SLC6A3CA1CA2CA5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108727524-B Internal electron donor compound and catalyst for catalyzing propylene polymerization 中国石油天然气股份有限公司 2020-08-07 CN claimed
CN-108727524-B Internal electron donor compound and catalyst for catalyzing propylene polymerization 中国石油天然气股份有限公司 2020-08-07 CN disclosed
US-10407376-B2 Method to prepare phenolics from biomass NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2019-09-10 US disclosed
US-20180033966-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME DUK SAN NEOLUX CO., LTD. (KR) 2018-02-01 US disclosed
US-20170349529-A1 Method to Prepare Phenolics from Biomass NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2017-12-07 US disclosed
EP-3245186-A1 METHOD TO PREPARE PHENOLICS FROM BIOMASS Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO (NL) 2017-11-22 EP disclosed
WO-2016114668-A1 METHOD TO PREPARE PHENOLICS FROM BIOMASS NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) 2016-07-21 WO disclosed
EP-1963294-B1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2012-10-10 EP disclosed
US-8119666-B2 1,2,5-thiazolidine derivatives useful for treating conditions mediated by protein tyrosine phosphatases (PTPase) NOVARTIS AG (CH) 2012-02-21 US disclosed
US-8084448-B2 Organic compounds NOVARTIS AG (CH) 2011-12-27 US disclosed
WO-2007067613-A1 1,2,5-THIAZOLIDINE DERIVATIVES USEFUL FOR TREATING CONDITIONS MEDIATED BY PROTEIN TYROSINE PHOSPHATASES (PTPASE) NOVARTIS AG (CH) 2007-06-14 WO disclosed
US-20060135582-A1 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof DIPHARMA S.P.A. (IT) 2006-06-22 US disclosed
EP-1581508-A1 A PROCESS FOR THE PREPARATION OF BENZO D ISOXAZOL-3-YL- METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF Dipharma S.p.A. (IT) 2005-10-05 EP disclosed
WO-2004063173-A1 A PROCESS FOR THE PREPARATION OF BENZO[D]ISOXAZOL-3-YL-METHANESULFONIC ACID AND THE INTERMEDIATES THEREOF DIPHARMA S.P.A. (IT) 2004-07-29 WO disclosed
US-6433214-B1 Process for the preparation of 2-(4-methylphenyl)-benzoic acid derivatives DIPHARMA S.P.A. (IT) 2002-08-13 US disclosed
EP-1044956-A1 A process for the preparation of 2-(4-methylphenyl) benzoic acid derivatives Dinamite Dipharma S.p.A. (IT) 2000-10-18 EP disclosed
US-5804532-A REACTING A BENZOYL ISOXAZOLE WITH A BASE RHONE-POULENC AGRICULTURE LIMITED (GB) 1998-09-08 US disclosed
US-5371063-A Herbicidal 4-benzoylisoxazoles RHONE-POULENC AGRICULTURE LIMITED (GB) 1994-12-06 US disclosed
EP-0625505-A2 2-Cyano-1,3-dione derivatives and their use as herbicides RHONE POULENC AGRICULTURE LTD. (GB) 1994-11-23 EP disclosed
EP-0609797-A1 4-Benzoyl isoxazoles and their use as herbicides RHONE POULENC AGRICULTURE LTD. (GB) 1994-08-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10407376-B2 Method to prepare phenolics from biomass FDPS, DNPH1, HPD L3MBTL1 4637/4885SLC6A3 4582/4885CA1 4426/4885
US-20170349529-A1 Method to Prepare Phenolics from Biomass FDPS, DNPH1, HPD L3MBTL1 4637/4885SLC6A3 4582/4885CA1 4426/4885
US-20180033966-A1 NOVEL COMPOUND FOR ORGANIC ELECTRIC ELEMENT, ORGANIC ELECTRIC ELEMENT USING THE SAME, AND ELECTRONIC DEVICE COMPRISING SAME EBPL, OR51E2, EML4 L3MBTL1 1325/4885SLC6A3 4293/4885CA1 1828/4885
US-20060135582-A1 Process for the preparation of benzo [d] isoxazol-3-yl-methanesulfonic acid and the intermediates thereof GABRD, GABRA5, GABRA6 L3MBTL1 4876/4885SLC6A3 1858/4885CA1 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.